The book has multiple tables and charts that are demonstrative and easy to follow. Marin and Escobar analyze relevant studies, including CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness), CUtLASS (Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study), STAR-D (Sequenced Treatment Alternatives to Relieve Depression), and STEP-BD (Systematic Treatment Enhancement Program for Bipolar Disorder), among others, using evidence-based recommendations for specific treatments. Less helpful are their “bottom line” recommendations that, at times, seem less feasible to follow. For example, in discussing extrapyramidal symptoms related to antipsychotics, they recommend, “whenever possible, decreasing the antipsychotic dose or switching medications rather than using adjunctive medication to control the adverse effects (p. 41).” This would be an ideal recommendation if you are treating a medication-naive patient, or one with few medication trials. I think, however, this recommendation should have been further expanded to discuss when, as often happens, you cannot apply their initial recommendation.